Quotient Limited is a diagnostics firm in the commercial stage, dedicated to the creation, production, marketing, and distribution of solutions for the global transfusion diagnostics sector. The company's reach extends across the United States, France, Japan, and other international territories. A central element of their product portfolio is MosaiQ, an exclusive technological platform. This system delivers extensive testing capabilities for immunohematology, alongside serological and molecular disease screening applications. Beyond the innovative MosaiQ platform, Quotient also provides traditional reagent products essential for blood grouping. These include antisera for identifying blood group antigens; reagent red blood cells designed to detect blood group antibodies; whole blood control products for daily quality assurance; and various ancillary items that support blood group analysis. Their specialized MosaiQ microarrays include several offerings: the SDS Microarray, crafted for serological disease screening to pinpoint cytomegalovirus and Syphilis; the MDS Microarray, which conducts molecular disease screening on donor red cells or source plasma; the IH Microarray for blood grouping; an Autoimmune Microarray; a COVID-19 specific array; and the IH3 Microarray. Quotient's diverse customer base encompasses healthcare institutions such as hospitals, blood donation centers, independent testing facilities, original equipment manufacturers, blood banking operations, and other diagnostic companies. Founded in 2007, the company maintains its headquarters in Eysins, Switzerland.